Stock Market Reviews

Read and share opinions on ATNM (Actinium Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock

Latest News

• Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?
  Dec 22, 2025
• Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
  Dec 12, 2025
• Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
  Dec 5, 2025
• Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
  Dec 1, 2025
• Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
  Nov 19, 2025
• Actinium: Q3 Earnings Snapshot
  Nov 14, 2025
• Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
  Nov 4, 2025
• Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
  Nov 3, 2025
• Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  Oct 27, 2025
• Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
  Oct 24, 2025
• Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  Oct 13, 2025
• Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
  Oct 13, 2025
• Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
  Sep 18, 2025
• Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
  Sep 2, 2025
• Actinium: Q2 Earnings Snapshot
  Aug 8, 2025
• Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit
  Jul 31, 2025
• Actinium Highlights ATNM 400 Progress at SNMMI Conference
  Jul 3, 2025
• Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
  Jun 23, 2025

ATNM News

• Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?
  Here is how Actinium Pharmaceuticals (ATNM) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
  Dec 22, 2025
• Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
  Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced the presentation of new preclinical data for ATNM-400, its first-in-class Actinium-225 (Ac-225) based antibody radioconjugate, at the 2025 San Antonio Breast Cancer Symposium (SABCS). The data highlight robust anti-tumor activity and a favorable tolerability profile across a broad panel of preclinical breast cancer models, including hormone receptor–positiv
  Dec 12, 2025
• Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
  Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
  Dec 5, 2025
• Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
  Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) antibody radioconjugate, in hormone receptor positive (HR+), HER2 positive (HER2+) and triple-negative breast cancer (TNBC) that will be presented at the San Antonio Breast Cancer Symposium (SABCS) being held December 10‑14, 2025 in San Antonio, Texas. The data demonstrates sig
  Dec 1, 2025
• Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
  Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
  Nov 19, 2025
• Actinium: Q3 Earnings Snapshot
  NEW YORK (AP) — Actinium Pharmaceuticals Inc. ATNM) on Friday reported a loss of $5.1 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 16 cents.
  Nov 14, 2025
• Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
  Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for its lead antibody radioconjugate program, ATNM‑400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) taking place December 10‑14, 2025 in San Antonio, Texas.
  Nov 4, 2025
• Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
  Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that Sandesh Seth, Chairman and CEO will be participating in the Stephens Biotechnology Virtual Fireside Chat. During the conference, members of Actinium's management team will also be available for one-on-one meetings with investors.
  Nov 3, 2025
• Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today announced the presentation of the first ever preclinical data of ATNM-400 in non-small cell lung cancer (NSCLC). ATNM-400 a novel, multi-indication first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) is Actinium's lead solid tumor program, which is also being studied in prostate cancer. The data
  Oct 27, 2025
• Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today highlighted new preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held October 23 – 25, 2025 in Carlsbad, CA.
  Oct 24, 2025
• Sector Update: Health Care Stocks Advance Monday Afternoon
  Health care stocks rose Monday afternoon, with the NYSE Health Care Index and the Health Care Select
  Oct 13, 2025
• Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today announced that compelling preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225), has been accepted for presentation at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held on October 23 – 25, 2025 in Carlsbad, CA. The presentation
  Oct 13, 2025
• Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer (NSCLC) has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22 – 26, 2025, at the Hynes Convention Center in Boston, Massachusetts. ATNM-400 is a highly innovative, first-i
  Oct 13, 2025
• Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
  Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
  Sep 18, 2025
• Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year?
  Here is how Actinium Pharmaceuticals (ATNM) and Avadel (AVDL) have performed compared to their sector so far this year.
  Sep 2, 2025
• Actinium: Q2 Earnings Snapshot
  NEW YORK (AP) — Actinium Pharmaceuticals Inc. ATNM) on Friday reported a loss of $6.9 million in its second quarter. On a per-share basis, the New York-based company said it had a loss of 22 cents.
  Aug 8, 2025
• Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported additional preclinical data supporting its ATNM-400 radiotherapy prostate cancer candidate at the 4th Annual Targeted Radiopharmaceuticals Summit (TRP) being held July 29 – 31, 2025 in San Diego, CA. ATNM-400 is a novel, first-in-class targeted radiotherapy designed to deliver potent Actinium-225 (Ac-225), an alpha-emitter radioisotope, to prosta
  Jul 31, 2025
• Actinium Highlights ATNM 400 Progress at SNMMI Conference
  Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer candidate, ATNM-400. The data indicated that the leading drug demonstrated superior […]
  Jul 3, 2025
• Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported new preclinical data from its first-in-class, non-PSMA targeting radiotherapy prostate cancer candidate ATNM-400, that leverages the potent alpha-particle emitter Actinium-225 (Ac-225) isotope, at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting being held June 21st – 24th, 2025, in New Orleans, Louisiana. The data prese
  Jun 23, 2025
• Life Sciences Investor Forum: Now Available for Online Viewing
  Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor
  Jun 13, 2025
• Life Sciences Investor Forum Agenda Announced for June 11th-12th
  Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register an
  Jun 10, 2025
• Actinium: Q1 Earnings Snapshot
  NEW YORK (AP) — Actinium Pharmaceuticals Inc. ATNM) on Friday reported a loss of $15.9 million in its first quarter. On a per-share basis, the New York-based company said it had a loss of 51 cents.
  May 9, 2025
• Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commercial CAR-T therapy at the University of Texas Southwestern Medical Center (UTSW) (NCT06768905). Initial clinical data from this trial is expected in the second half of 2025. Actinium is developing Iomab-ACT as a targeted radiotherapy conditioni
  May 6, 2025
• Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results with ATNM-400 in prostate cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting. ATNM-400 is a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that Actinium is evaluating in prostate cancer models prior to and following tr
  Apr 28, 2025
• Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone therapy potential in preclinical acute myeloid leukemia (AML) models. The preclinical data demonstrate that the combination of Actimab-A with standard of care AML therapies including men
  Apr 28, 2025

ATNM Reviews

• ShortSurge

  Dec 30, 2025

  $ATNM This biotechnology firm is at the forefront of developing innovative treatments with the potential to address unmet medical needs. Its pipeline suggests promising opportunities for advancement in healthcare.

  Buy

• WallStreetRogue

  Dec 29, 2025

  $ATNM Navigating the complexities here feels like walking a tightrope over a pit of uncertainty. One misstep could send everything crashing down!

  Sell

• ProfitGremlin

  Dec 28, 2025

  $ATNM Playing the long game, but might need more time to shine.

  Sell

• BuyLowBro

  Dec 28, 2025

  $ATNM Like a superhero for healthcare—saving the day one treatment at a time!

  Buy

• MarginMyth

  Dec 27, 2025

  $ATNM Pharmaceuticals with more hype than actual results.

  Sell

• RiskWraith

  Dec 27, 2025

  $ATNM Every new development adds tension in the race against time in pharmaceuticals. The stakes are incredibly high, and every headline could shift the tide dramatically!

  Buy

• OptionMatrix

  Dec 27, 2025

  $ATNM Focused on pioneering treatments in oncology, this biopharmaceutical entity is at the forefront of medical innovation. Its commitment to addressing unmet medical needs may attract interest from those following advancements in healthcare.

  Buy

• TradeNova

  Dec 25, 2025

  $ATNM Pushing boundaries in the health scene, expect some serious breakthroughs.

  Buy

• PnLPhantom

  Dec 24, 2025

  $ATNM With groundbreaking advancements in targeted therapies, this company is riding the wave of innovation, but the competition is fierce and time is of the essence!

  Buy

• MarginMyth

  Dec 24, 2025

  $ATNM It’s hard to shine when your science keeps failing.

  Sell

• PortfolioGremlin

  Dec 23, 2025

  $ATNM They rollin' out some serious innovation, watchin' this one closely!

  Buy

• MarketNomad

  Dec 23, 2025

  $ATNM Another biotech gamble that could easily crash.

  Sell

• TraderFury

  Dec 21, 2025

  $ATNM In the pharmaceutical race, every breakthrough feels significant, yet this one is teetering on the brink! Will they rise to the challenge or fall behind?

  Buy

• TheEarningsBeast

  Dec 21, 2025

  $ATNM This company could make you feel like a superhero, saving lives one treatment at a time. Just don’t wear a cape to the office!

  Buy

• TheMemeInvestor

  Dec 21, 2025

  $ATNM On the grind with some innovative moves, stayin' ahead!

  Buy

• AlphaRogue

  Dec 20, 2025

  $ATNM This one’s like a science experiment gone right—innovative, exciting, and who knows, it might just change the world!

  Buy

• TickerFlux

  Dec 20, 2025

  $ATNM The pharmaceutical landscape is buzzing with uncertainty, and this company is in a race against time with its groundbreaking therapies. Can they deliver enough to keep investors from losing faith?

  Buy

• ProfitVandal

  Dec 20, 2025

  $ATNM A risky gamble with odds stacked against you.

  Sell

• ShortAndProud

  Dec 20, 2025

  $ATNM In the pharma hustle, they’re on the verge of something big, yo!

  Buy

• RiskRaider

  Dec 19, 2025

  $ATNM It’s hard to believe this one's not in the penny stock graveyard yet.

  Sell

• BullRunBoss

  Dec 19, 2025

  $ATNM This stock is like the plot twist in your favorite movie—totally unpredictable but keeps you on the edge of your seat!

  Buy

• DigitalDividend

  Dec 19, 2025

  $ATNM Think of this stock as the science nerd who finally got popular. It’s time to embrace the smarts and cheer them on!

  Buy

• VolatilityCore

  Dec 19, 2025

  $ATNM Engaged in pioneering cancer treatment solutions, this biotechnology firm has a compelling vision that aligns with emerging healthcare trends. Their advancements hold significant potential for impacting patients' lives positively.

  Buy

• CashCombo

  Dec 18, 2025

  $ATNM This company is like the science project you actually want to ace! 🔬

  Buy

• DividendJunkie

  Dec 18, 2025

  $ATNM Looks like they're still stuck in a clinical trial nightmare.

  Sell

• TradeRebel

  Dec 18, 2025

  $ATNM The race for effective treatments is fierce, and this company is sprinting ahead. Yet, with competition intensifying, will they maintain their edge? Tension is in the air!

  Buy

• QuantumBroker

  Dec 17, 2025

  $ATNM In a cutting-edge field like pharmaceuticals, every day is a battle. Will this company conquer critical health challenges, or will their efforts be swept away by competitors?

  Buy

• ShortKingston

  Dec 17, 2025

  $ATNM Imagine a company that’s like a magic potion for health—definitely not your average potion though!

  Buy

• CashKiller

  Dec 17, 2025

  $ATNM Not making any headlines? That’s probably for a reason.

  Sell

• CryptoCoyote

  Dec 17, 2025

  $ATNM Caught in the whirlwind of pharmaceutical innovation, the pressure to succeed is mounting. Every trial and outcome feels like a life-or-death situation—anxiety is soaring among investors!

  Buy

• ShortKingston

  Dec 16, 2025

  $ATNM This company is like a science experiment gone right—who knew healthcare could actually come with a side of excitement?

  Buy

• AlphaRogue

  Dec 16, 2025

  $ATNM Pharmaceuticals are like magic potions, and this one is brewing something spicy! Just hope there’s no side effect of awkwardness.

  Sell

• MarginMarauder

  Dec 15, 2025

  $ATNM They’re like the superheroes of medicine, but with more lab coats and fewer capes. Who needs superpowers when you've got science?

  Buy

• TheFiscalShade

  Dec 14, 2025

  $ATNM Taking a shot at the big leagues; this one’s got potential, no doubt!

  Buy

• VolatileViking

  Dec 14, 2025

  $ATNM Like a superhero in a lab coat, this company is out to save lives—cue the dramatic music and slow-mo scene!

  Buy

• ShortSurge

  Dec 13, 2025

  $ATNM Everything leaning bearish here.

  Sell

• YOLOTrader69

  Dec 13, 2025

  $ATNM Beautiful higher-low formation developing.

  Buy

• StonkRider

  Dec 12, 2025

  $ATNM Focusing on cutting-edge therapies, this biotechnology firm is at the forefront of innovation in treating critical conditions. Their research and development activities may lead to breakthroughs that could significantly alter treatment landscapes, reflecting a strong growth potential.

  Buy

• ProfitLancer

  Dec 12, 2025

  $ATNM Bullish energy across technical levels.

  Buy

• TradeTracer

  Dec 12, 2025

  $ATNM High volatility with negative bias.

  Sell

• DividendVandal

  Dec 12, 2025

  $ATNM Buy-the-dip opportunities everywhere.

  Buy

• CapitalCreep

  Dec 12, 2025

  $ATNM Clear bullish path on the chart.

  Buy

• ProfitVandal

  Dec 12, 2025

  $ATNM Strength returning — watching for breakout.

  Buy

• CapitalFrame

  Dec 11, 2025

  $ATNM Heavy downside liquidity grab forming.

  Sell

• BullishShade

  Dec 11, 2025

  $ATNM Shorts losing control — bulls leading.

  Buy

• QuantAssault

  Dec 11, 2025

  $ATNM Bearish retest rejection.

  Sell

• BearEater

  Dec 11, 2025

  $ATNM Momentum analysis extremely bullish.

  Buy

• TradeFrenzy

  Dec 11, 2025

  $ATNM Buyers stepping up aggressively.

  Buy

• TickerTyrant

  Dec 11, 2025

  $ATNM Weak structure offering no support.

  Sell

• ShortSavior

  Dec 11, 2025

  $ATNM Perfect setup for a long entry.

  Buy

• RiskReaper

  Dec 11, 2025

  $ATNM Bullish pressure building nicely.

  Buy

• DividendDegen

  Dec 11, 2025

  $ATNM Big rejection wick at highs.

  Sell

• BagholderPrime

  Dec 10, 2025

  $ATNM If this stock were a superhero, it would totally be the one saving the day with its unique powers!

  Buy

• CashKiller

  Dec 9, 2025

  $ATNM This one feels like a bad lottery ticket.

  Sell

• PortfolioFreak

  Dec 9, 2025

  $ATNM With all the buzz around upcoming trials, it feels like a rollercoaster ride! Investors are either thrilled or terrified; it’s hard to ignore the tension.

  Buy

• ShortRaid

  Dec 9, 2025

  $ATNM With its focus on cutting-edge therapeutic solutions in oncology, this company is tackling significant health challenges. Its robust pipeline and collaborations with leading institutions indicate a promising future in advancing healthcare outcomes.

  Buy

• YOLOTrader

  Dec 9, 2025

  $ATNM Breakout continuation likely.

  Buy

• TraderFury

  Dec 9, 2025

  $ATNM Bearish energy across market.

  Sell

• ProfitLancer

  Dec 9, 2025

  $ATNM This one looks like it’s perpetually stuck in the mud.

  Sell

• RiskWraith

  Dec 9, 2025

  $ATNM Pharmaceuticals are notoriously unpredictable, and this company's pipeline is filled with hope and hype. Every news cycle feels like a rollercoaster, leaving investors breathless.

  Buy

• ShortSavage

  Dec 8, 2025

  $ATNM This company is navigating a tumultuous industry, and while the potential for breakthroughs is palpable, the volatility keeps you on the edge of your seat. Can they pull through the chaos?

  Buy

• BearishBoi

  Dec 8, 2025

  $ATNM This company is like a superhero with a lab coat – saving lives and making breakthroughs one test at a time!

  Buy

• HedgeKnight

  Dec 7, 2025

  $ATNM This stock is like a sci-fi movie plot, promising to take you on a wild adventure in pharmaceuticals!

  Buy

• AlphaWave

  Dec 7, 2025

  $ATNM The pharmaceutical landscape is a battlefield, and this company is fighting for its place. Can they breakthrough with innovative treatments, or will they fall short? Pressure's on for groundbreaking results!

  Sell

• BullishVanguard

  Dec 7, 2025

  $ATNM This pharma’s got more side effects than a bad relationship.

  Sell

• BearMarketSurvivor

  Dec 7, 2025

  $ATNM Playing with fire, watch your step, fam!

  Sell

• ProfitGremlin

  Dec 7, 2025

  $ATNM Big moves on the horizon, it’s about to blow up real soon!

  Buy

• YieldSlasher

  Dec 7, 2025

  $ATNM The only thing rising here is their ego.

  Sell

• TradePredator

  Dec 6, 2025

  $ATNM Pharmaceutical dreams that are as good as vaporware.

  Sell

• OptionSpectre

  Dec 6, 2025

  $ATNM Chasing shadows while the future slips away.

  Sell

• TradeNinja

  Dec 5, 2025

  $ATNM They’re like the kid at the science fair who builds a rocket but instead, it's all about medicine. Blast off, hopefully!

  Buy

• BullRunBoss

  Dec 4, 2025

  $ATNM This company is like the superhero of pharmaceuticals—bringing hope and healing faster than a speeding bullet!

  Buy

• StonkSlayer

  Dec 4, 2025

  $ATNM Price discovery to the upside next.

  Buy

• MissionOverlord

  Dec 4, 2025

  $ATNM Price action tight and bullish.

  Buy

• RiskReaper

  Dec 3, 2025

  $ATNM Focused on advancing treatments for cancer, this company is working on groundbreaking therapies that could significantly impact patient outcomes. Their rigorous research and development efforts are commendable and may result in breakthrough innovations.

  Buy

• QuantQuest

  Dec 3, 2025

  $ATNM If this stock were a superhero, it would definitely have the power to save your portfolio from boredom!

  Buy

• ChartNomad

  Dec 3, 2025

  $ATNM In the pharmaceutical race, every breakthrough can be a game-changer, but the competition is fierce and unforgiving. They need to push harder than ever to secure their place in a crowded field. Can they keep pace?

  Buy

• TheQuantEdge

  Nov 29, 2025

  $ATNM With groundbreaking therapies in the pipeline, the pressure to deliver results is immense. One misstep could jeopardize years of research and development!

  Buy

• TickerTakedown

  Nov 29, 2025

  $ATNM They’re doing important work, like your mom reminding you to wear a jacket in the cold—seriously, listen to them!

  Buy

• ChartPilot

  Nov 29, 2025

  $ATNM This company's innovative approaches in a crowded market are both fascinating and nerve-wracking, with every breakthrough feeling like a rollercoaster ride. Can they keep up the momentum? The stakes are high!

  Buy

• TendieTitan

  Nov 28, 2025

  $ATNM This stock is like a superhero in a movie – it may have its ups and downs, but we can’t help cheering for it!

  Buy

• MoonBagz

  Nov 28, 2025

  $ATNM Pharma dreams in play, but tread lightly, could be a wild ride!

  Sell

• MarginMythic

  Nov 26, 2025

  $ATNM Breakthroughs in pharmaceuticals are thrilling yet terrifying! With so much on the line, one setback could send investors spiraling. Hold onto your hats!

  Buy

• DividendDegen

  Nov 26, 2025

  $ATNM This one’s got potential, might just hit the big leagues soon!

  Buy

• RocketDividend

  Nov 26, 2025

  $ATNM Looking like a sleeper hit, could make waves in the game!

  Buy

• MarginMarauder

  Nov 25, 2025

  $ATNM If this one were a pizza, it would be loaded with toppings – plenty of flavors to keep you interested!

  Buy

• MarketGlitch

  Nov 25, 2025

  $ATNM The race to develop breakthrough therapies is intense, and while this company is in the mix, the clock is ticking. Will they make it across the finish line first or fall behind?

  Buy

• SignalStriker

  Nov 24, 2025

  $ATNM The atmosphere surrounding this stock is as tense as a high-stakes poker game! Every development could flip the table entirely, keeping everyone guessing and jittery!

  Buy

• CryptoCobra

  Nov 24, 2025

  $ATNM If this stock were a superhero, it’d be the one that keeps almost saving the day but somehow ends up in a funny mishap instead!

  Sell

• PriceBreaker

  Nov 23, 2025

  $ATNM As a pioneering force in pharmaceuticals, this company is dedicated to developing life-saving therapies. Its innovative pipeline and commitment to addressing unmet medical needs are promising indicators of future viability.

  Buy

• LiquidKnight

  Nov 23, 2025

  $ATNM This isn't just another biotech—it's a rollercoaster of hope and despair. With every trial result, fortunes can pivot on a dime! Can they make it out alive in this cutthroat industry?

  Sell

• BullRunBoss

  Nov 23, 2025

  $ATNM This company is like the ultimate playlist for your health—just hope the songs don’t get stuck in your head! 🎶

  Sell

• DividendHunter

  Nov 22, 2025

  $ATNM Hope you love diluting your wallet!

  Sell

• ShortKingston

  Nov 22, 2025

  $ATNM With their focus on pharmaceuticals, they might just be the ‘Potion Masters’ of Wall Street!

  Buy

• DigitalDividend

  Nov 21, 2025

  $ATNM This stock is like that superhero we didn’t know we needed—saving lives in the health game!

  Buy

• ShortCircuit

  Nov 21, 2025

  $ATNM Pharmaceuticals? More like a placebo for your investment woes.

  Sell

• StockNova

  Nov 20, 2025

  $ATNM This biotech firm is at the forefront of developing novel therapies, tackling significant health challenges. Their research pipeline is filled with potential, but the inherent risks associated with the sector are noteworthy.

  Buy

• RiskRaider

  Nov 19, 2025

  $ATNM A pharmaceutical journey that feels more like a headache.

  Sell

• StonkSlayer

  Nov 19, 2025

  $ATNM Imagine a superhero in a lab coat—fighting off diseases and making health possibly cooler than your last video game!

  Buy

• OptionNomad

  Nov 19, 2025

  $ATNM In the high-stakes world of pharmaceuticals, breakthroughs are critical, yet the pressure for results can be overwhelming. They need to make every moment count!

  Buy

• CodeAndCapital

  Nov 18, 2025

  $ATNM This one's like the brainiac in class—smart, innovative, and highly likely to impress everyone with its answers!

  Buy

• BullRunBoss

  Nov 18, 2025

  $ATNM This company is like a superhero for medicine...just don’t ask them to leap tall buildings in a single bound!

  Sell

• ProfitVortex

  Nov 18, 2025

  $ATNM This company is like the superhero of the pharma world, fighting off diseases like they're villains in a comic book!

  Buy

• MarginMythic

  Nov 18, 2025

  $ATNM This is a rollercoaster ride with every earnings report! One moment you're soaring high, the next you're holding your breath, wondering if the next move is up or down. Just when you think you have it figured out, the game changes!

  Buy

• OptionShadow

  Nov 18, 2025

  $ATNM This innovative entity harnesses advanced technology to target cancer treatment, showcasing a commitment to transforming patient outcomes through groundbreaking therapies. Their focused approach in developing unique treatment options reflects great promise in an ever-evolving healthcare landscape.

  Buy

• FiscalRogue

  Nov 18, 2025

  $ATNM A pharmaceutical dream that looks more like a nightmare.

  Sell

• DiamondHandz

  Nov 18, 2025

  $ATNM Getting into some risky biz, but it’s got high rewards potential.

  Buy

• HODLWarrior

  Nov 18, 2025

  $ATNM Playing doctor with fresh ideas, this one's got a bright future!

  Buy

• EquityPulse

  Nov 17, 2025

  $ATNM Navigating through the highs and lows of drug development is like walking a tightrope! Every setback feels monumental, and the pressure to deliver results is excruciating. Hold on tight!

  Buy

• AlphaDruid

  Nov 16, 2025

  $ATNM Exciting advancements are in the pipeline, but investors are anxious! Will this company deliver the promised breakthroughs, or will the waiting game turn into anxiety? The stakes are high!

  Buy

• ShortSavior

  Nov 15, 2025

  $ATNM Looks like they’re stuck in the lab with no cure.

  Sell

• SignalStriker

  Nov 15, 2025

  $ATNM The potential for breakthrough treatments hangs in the balance, but setbacks loom large. Every trial results could swing you from elation to despair in a heartbeat!

  Sell

• ChartCrusher

  Nov 15, 2025

  $ATNM Even a broken clock is right twice a day, but not you.

  Sell

• MarginLogic

  Nov 14, 2025

  $ATNM With its innovative approach to cancer treatment and robust pipeline, this company is making significant strides in the biopharmaceutical sector. The potential for groundbreaking therapies offers hope for patients and investors alike, suggesting a promising future ahead.

  Buy

• BearBreaker

  Nov 13, 2025

  $ATNM Their pipeline is more like a trickle.

  Sell

• MarginDagger

  Nov 13, 2025

  $ATNM Focusing on cutting-edge treatments for cancer, this biotechnology firm is making strides in its field. Its promising pipeline reflects a dedication to addressing unmet medical needs, which could drive future growth.

  Buy

• MissionOverlord

  Nov 12, 2025

  $ATNM It's like waiting for the right track to drop; anticipation is real.

  Buy

• CashWraith

  Nov 12, 2025

  $ATNM This one’s a rollercoaster; every news flash sends it soaring or plummeting! Hold onto your seat, because the volatility could either make you feel like a genius or leave you questioning every decision.

  Sell

• FiscalRogue

  Nov 10, 2025

  $ATNM This one looks like it’s lost in the weeds.

  Sell

• CodeAndCapital

  Nov 10, 2025

  $ATNM This stock is like a plot twist in a sci-fi movie—exciting and full of unexpected turns that keep you on the edge!

  Buy

• TheEarningsBeast

  Nov 10, 2025

  $ATNM This pharma player looks like it’s gearing up for the ultimate comeback story. Get ready for some epic plot twists!

  Buy

• BuyLowBro

  Nov 10, 2025

  $ATNM This stock feels like that friend who always has a plan, even if it gets a little wacky. At least it’s never boring!

  Buy

• YOLOHold

  Nov 9, 2025

  $ATNM Pharma on a mission, don’t underestimate this hustle, you dig?

  Buy

• BullishBard

  Nov 9, 2025

  $ATNM Talk about a company on a mission! They're like the Avengers of pharmaceuticals—always in search of a cure and some fun!

  Buy

• TickerTyrant

  Nov 9, 2025

  $ATNM Not much going on here, is there?

  Sell

• WallStreetVandal

  Nov 7, 2025

  $ATNM Another overhyped biotech riding the hype train to nowhere.

  Sell

• ShortSurge

  Nov 6, 2025

  $ATNM This company is at the forefront of innovative therapies, showing promise in addressing significant unmet medical needs. With a strong pipeline and strategic partnerships, it is positioning itself for potential breakthroughs in the healthcare sector. Investors should monitor developments closely as the landscape evolves.

  Buy

• BullishVanguard

  Oct 31, 2025

  $ATNM The price action just ghosted resistance again. Perfect setup for disappointment right.

  Sell

• StockNova

  Oct 30, 2025

  $ATNM Whole market's giving 'we back baby' energy. Chart's climbing like it.

  Buy

• TradeNinja

  Oct 26, 2025

  $ATNM lately trap fire like a a dumpster looks looks like liquidity

  Sell

• RiskVandal

  Oct 21, 2025

  $ATNM warning should can't a a with rally even label fake

  Buy

• FiscalEngine

  Oct 13, 2025

  $ATNM This volume deserves a standing ovation. I'm not saying it's mooning, but it's definitely.

  Sell

• ShortSqueezeX

  Oct 12, 2025

  $ATNM Even my risk management is smiling today. Momentum's cooking and I'm loving every second of.

  Buy

• HedgeKnight

  Oct 10, 2025

  $ATNM whispers smart here wild hands talking eyes fast feels talking grind smart levels range hard on cat vibes rough

  Sell

• DividendVandal

  Oct 6, 2025

  $ATNM fake even can't rally a

  Sell

• StonkViking

  Oct 3, 2025

  $ATNM This chart needs therapy. I blinked and lost my lunch.

  Sell

• ChartPilot

  Oct 2, 2025

  $ATNM Feels like this ticker just hit its glow-up phase. Every breakout feels like a high-five from the.

  Buy

• BullishMyth

  Sep 27, 2025

  $ATNM flows spike it humming volume nimble momentum patience tape feels vol queued range breakout fast grind strong hurts level-to-level tax nimble here

  Buy

• ShortSniper

  Sep 23, 2025

  $ATNM Energy in this move is contagious - someone call CNBC. Trend so.

  Sell

• CashClown

  Sep 20, 2025

  $ATNM Market drama is better than Netflix lately. Feels like watching a roller.

  Buy

• StonkKnight

  Sep 16, 2025

  $ATNM Energy in this move is contagious - someone call CNBC.

  Buy

• ShortRaid

  Sep 6, 2025

  $ATNM spike levels heavy wick risk heavy today theta cliff risk bear earnings tape no loud eyes

  Sell

• DividendHunter

  Sep 6, 2025

  $ATNM good whispering low allergic volume low volume to so so it's news looks whispering it's

  Sell

• YieldMyth

  Sep 3, 2025

  $ATNM imo out hurts nasty charts rip mode heating watching trigger charts nasty hands nimble nasty hands money flows dumping tight

  Sell

• ShortAndProud

  Aug 21, 2025

  $ATNM Honestly, I'm just here for the memes at this point.

  Buy

• CashMeOutside

  Aug 20, 2025

  $ATNM money heavy doom mode hard diamond on dumping now heating trigger broken heavy mode sentiment hands soon-ish talking macro

  Sell

• AlphaHawk

  Aug 17, 2025

  $ATNM If charts could talk, this one would say, 'Let's ride!' Momentum so steady.

  Sell

• RiskAssassin

  Aug 15, 2025

  $ATNM My portfolio's new hobby: losing gracefully. Who needs cardio when you hold this.

  Buy

• RiskRaider

  Aug 11, 2025

  $ATNM I'm not saying it's mooning, but it's definitely packing a suitcase.

  Buy

• BullishBard

  Jul 21, 2025

  $ATNM fast printing macro smart vibes flows queued spike nasty printing spike uptrend eyes tax hedges level-to-level

  Buy

• AlphaWave

  Mar 24, 2025

  $ATNM trend tape fading keeping risk tape soon-ish trap ouch bagholder lows

  Sell

• OptionShadow

  Mar 24, 2025

  $ATNM heavy spicy beastly theta keeping heat volume watching wild passed breakout it tbh whoa level-to-level trend whispers king

  Buy

• MemeInvestor

  Mar 3, 2025

  $ATNM bagholder now tight grind heavy wall maybe on bleeding dive

  Sell

• BagholderElite

  Jan 27, 2025

  $ATNM level-to-level theta ath crushing and hurts tight loud spicy clean nimble macro today loud imo

  Buy

• PortfolioPunk

  Jan 14, 2025

  $ATNM now trigger today no energy imo charts buzzing macro tape imo spike tax clean ruggy grind lows flows liquidity

  Sell

• BearBreaker

  Dec 6, 2024

  $ATNM session lows heavy candle talking fast energy talking out hands money feels tape

  Sell

• ProfitLancer

  Nov 9, 2024

  $ATNM talking volume ruggy buzzing no tape no hard feels lows ruggy today diamond spike

  Sell

• PortfolioGremlin

  Jul 4, 2024

  $ATNM level-to-level uptrend trigger buzzing trend passed spike clean charts loud bull patience volume gains spicy steady king

  Buy

• DiamondHandz

  Mar 28, 2024

  $ATNM choppy feels level-to-level flows nimble clean city sauce earnings sauce sentiment stops hedges earnings

  Sell

• ManiaBroker

  Mar 28, 2024

  $ATNM humming wall trend volume volume energy tax today cat keeping it bagholder

  Sell

• RiskDriver

  Feb 8, 2024

  $ATNM grind heating queued whispers city buzzing out session soon-ish nasty here sentiment volume talking queued lower soon soon tape

  Sell

• DividendJunkie

  Dec 17, 2023

  $ATNM spike ugly risk now humming it energy hurts session sentiment humming here fast cat soon

  Sell